These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21561734)

  • 1. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of methods for classifying samples as truly specific with confirmatory immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Allacher P; Horling F
    J Pharm Biomed Anal; 2014 Jan; 88():27-35. PubMed ID: 24013033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.
    Gupta S; Devanarayan V; Finco D; Gunn GR; Kirshner S; Richards S; Rup B; Song A; Subramanyam M
    J Pharm Biomed Anal; 2011 Jul; 55(5):878-88. PubMed ID: 21531522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J; Schantz A; Schwegler M; Shankar G
    J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody.
    Liao K; Sikkema D; Wang C; Chen K; DeWall S; Lee TN
    J Immunol Methods; 2012 Jan; 375(1-2):258-63. PubMed ID: 22001556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera.
    Shin SK; Ha SK; Lee KW; Yoo TH; Yun SR; Yoon SH; Kim SJ; Lee SK; Heo TH
    J Pharm Biomed Anal; 2010 Jun; 52(2):289-93. PubMed ID: 20133098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
    Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
    J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals.
    Wadhwa M; Gaines-Das R; Thorpe R; Mire-Sluis A
    Dev Biol (Basel); 2005; 122():155-70. PubMed ID: 16375260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
    Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
    J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity assessment in non-clinical studies.
    Swanson SJ; Bussiere J
    Curr Opin Microbiol; 2012 Jun; 15(3):337-47. PubMed ID: 22770538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.
    Araujo J; Zocher M; Wallace K; Peng K; Fischer SK
    J Pharm Biomed Anal; 2011 Jul; 55(5):1041-9. PubMed ID: 21466939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: an assessment.
    Cobo A; Martín-Suarez A; Calvo MV; Domínguez-Gil A; de Gatta MM
    Ther Drug Monit; 2010 Apr; 32(2):169-76. PubMed ID: 20216123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies.
    Geng D; Shankar G; Schantz A; Rajadhyaksha M; Davis H; Wagner C
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):364-75. PubMed ID: 15963677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.